Fig. 3.

Maintenance of LDA (A) and remission (B) at week 52 among week-24 responders (guselkumab-randomized patients)

n represents the total number of patients with response at week 24. Through week 24, patients meeting treatment failure criteria or with missing data were considered non-responders. After week 24 and through week 52, patients with missing data were considered non-responders. DAPSA: Disease Activity Index for Psoriatic Arthritis; GUS: guselkumab; LDA: low disease activity; MDA: minimal disease activity; PASDAS: Psoriatic Arthritis Disease Activity Score; Q4W: every 4 weeks; Q8W: every 8 weeks; VLDA: very low disease activity.